D-Wave Quantum Inc. QBTS CEO Alan Baratz has criticized Nvidia Corp. NVDA CEO Jensen Huang for his comments regarding the timeline for achieving practical quantum computing, saying he is “dead wrong.”
What Happened: Huang’s remarks during Nvidia's analyst day, suggesting a 15 to 30-year wait for “very useful quantum computers,” have sparked a heated debate in the tech community.
Baratz strongly disagreed with Huang’s timeline, stating that D-Wave’s quantum computers are already in commercial use by companies like Mastercard Inc. MA and Japan’s NTT Docomo, reported CNBC.
"Not 30 years from now, not 20 years from now, not 15 years from now," he stated, adding, "But right now today."
Baratz stated that while Huang's remarks may hold some validity for gate model quantum computers, they are “100% off base” when it comes to annealing quantum computers.
He expressed willingness to meet with Huang to discuss the capabilities of D-Wave’s technology, highlighting that their systems can tackle problems beyond the reach of Nvidia’s fastest systems.
"I'll be happy to meet with Jensen any time, any place, to help fill in these gaps for him," the D-Wave CEO said.
Subscribe to the Benzinga Tech Trends newsletter to get all the latest tech developments delivered to your inbox.
Why It Matters: After Huang’s comments, quantum computing stocks experienced significant declines on Wednesday.
During regular trading hours, IonQ Inc. IONQ dropped by 39%, while Quantum Computing Inc. QUBT saw a 43.34% decline.
D-Wave and Rigetti Computing Inc. RGTI also faced declines, with their stocks falling by 36.13% and 45.41%, respectively.
Price Action: D-Wave’s stock tumbled by 36.13% on Wednesday, but rebounded in after-hours trading with a 6.39% increase, reaching $6.49. Despite the decline, the company’s shares have skyrocketed by 600% over the past year, according to Benzinga Pro data.
Check out more of Benzinga’s Consumer Tech coverage by following this link.
Read Also:
Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
